医学
彭布罗利珠单抗
细胞因子释放综合征
细胞因子
肺癌
癌症
内科学
不利影响
免疫疗法
肿瘤科
嵌合抗原受体
作者
C. Normand,Hervé Zender,Dominique M Staehli,Amina Faiza Chouiter-Djebaili,Gregor John
标识
DOI:10.1177/1078155220980813
摘要
Introduction The use of programmed death-ligand 1 (PD-L1) checkpoint inhibitor therapy is expanding, although its adverse effects are not completely known. We report on a rare case of acute cytokine release syndrome related to pembrolizumab use in a patient with lung cancer. Case report A 79-year-old man with metastatic, PD-L1-positive, non-small-cell lung cancer developed a febrile condition associated with a systemic inflammatory response syndrome and suffered haemodynamic compromise four hours after the first intravenous administration of pembrolizumab. A thorough medical workup found no alternative cause and a grade 2 cytokine release syndrome (CRS) was diagnosed. Management and outcome: Aggressive fluid resuscitation and supportive therapy led to restitutio ad integrum. Discussion Acute CRS after the administration of a PD-L1 inhibitor is infrequent but could be a fatal condition. Supportive treatment and, if necessary, corticosteroids should be considered.
科研通智能强力驱动
Strongly Powered by AbleSci AI